Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

Commitments and Contingencies (Details) - USD ($)
1 Months Ended 3 Months Ended
Apr. 04, 2021
Nov. 06, 2020
Apr. 15, 2021
Feb. 25, 2021
Jul. 25, 2019
Mar. 31, 2021
Mar. 30, 2021
Mar. 31, 2020
Commitments and Contingencies (Details) [Line Items]                
Transactions fee         $ 1,500,000      
Shares issued to settle transaction fee (in Shares)   150,000            
Pre and post judgement interest and attorney's fees           $ 1,500,000    
Issuance of shares (in Shares) 150,000              
Litigation Settlement, Amount Awarded to Other Party $ 300,000              
Operating Lease Expenses           0   $ 17,397
Percentage of consultant bonus             50.00%  
Shares issues (in Shares)             100,699  
Fee owed to consultant           $ 15,000,000    
Termination of agreement, description           In the event the A&R Agreement is terminated without cause by the Company, or by the CEO for good reason, the Company agreed to pay him the lesser of 18 months of salary or the remaining term of the agreement, the payment of any accrued bonus from the prior year, his pro rata portion of any current year’s bonus and health insurance premiums for the same period that he is to receive severance payments (as discussed above).    
Termination employment agreement           6 days    
Severance pay to paid upon termination of CFO without cause           3 months    
Consulting Agreement [Member]                
Commitments and Contingencies (Details) [Line Items]                
Related party transaction, description           On February 22, 2021, the Company entered into a consultancy agreement (as amended, the “Consulting Agreement”) with a related party (the “Consultant”). The Consulting Agreement is effective December 1, 2020. Pursuant to the Consulting Agreement, the Company agreed to pay the Consultant 15,000 British Pounds (GBP) per month (approximately $20,800) during the term of the agreement, increasing to 23,000 GBP per month (approximately $32,000) on the date (a) of publication of the data from the phase 2b clinical trial for Dupuytren’s disease (RIDD) and (b) the date that the Company has successfully raised over $15 million in capital. The Company also agreed to pay the Consultant the following bonus amounts: ● The sum of £100,000 (approximately $138,000) upon submission of the Dupuytren’s disease clinical trial data for publication in a peer-reviewed journal (“Bonus 1”); ●The sum of £434,673 GBP (approximately $605,000) (“Bonus 2”), which is earned and payable upon the Company raising a minimum of $15 million in additional funding, through the sale of debt or equity, after December 1, 2020 (the “Vesting Date”). Bonus 2 is payable within 30 days of the Vesting Date and shall be and shall not be accrued, due or payable prior to the Vesting Date. Bonus 2 is payable, at the election of the Consultant, at least 50% (fifty percent) in shares of the Company’s common stock, at the lower of (i) $3.00 per share, or (ii) the trading price on the date of the grant, with the remainder paid in GBP. ●The sum of £5,000 (approximately $7,000) on enrollment of the first patient to the phase 2 frozen shoulder trial (“Bonus 3”); and ●The sum of £5,000 (approximately $7,000) for enrollment of the first patient to the phase 2 delirium/POCD trial (“Bonus 4”).    
StanfordMember | KatexcoMember                
Commitments and Contingencies (Details) [Line Items]                
Shares issues (in Shares)     37,715          
Percentage of consultant additional bonus     19.00%          
KBL [Member]                
Commitments and Contingencies (Details) [Line Items]                
Damages of net tangible asset in business combination   $ 5,000,001            
Chief Executive Officer [Member]                
Commitments and Contingencies (Details) [Line Items]                
Employment agreement of chief executive officer term           3 years    
CEO’s annual base salary       $ 450,000        
Percentage of automatic annual salary increase       5.00%        
salary available to paid bonus           45.00%    
Notice period required to terminate the employment agreement           60 days    
Chief Financial Officer [Member]                
Commitments and Contingencies (Details) [Line Items]                
Notice period required to terminate the employment agreement           60 days    
Annual base salary       $ 300,000        
Target bonus Percentage       30.00%        
Accrued bonus payable           $ 15,750